Buy Fluvoxamine (Luvox) Cas 54739-18-3
Buy Fluvoxamine (Luvox) Cas 54739-18-3
Buy Fluvoxamine (Luvox) Cas 54739-18-3
Fluvoxamine, sold under the brand name Luvox among others, is an antidepressant of the selective serotonin reuptake inhibitor (SSRI) class.[8] It is primarily used to treat major depressive disorder and, perhaps more-especially, obsessive–compulsive disorder (OCD),[9] but is also used to treat anxiety disorders[10] such as panic disorder, social anxiety disorder, and post-traumatic stress disorder.[11][12][13]
Fluvoxamine’s side-effect profile is similar to that of other SSRIs. Common adverse effects include constipation, gastrointestinal problems, headache, anxiety, irritation, sexual problems, dry mouth, sleep problems, and an increased risk of suicide at the start of treatment. These effects appear to be significantly weaker than with other SSRIs, with the exception of gastrointestinal side-effects.[14]
Fluvoxamine appears to be more tolerable than other SSRIs, particularly with respect to cardiovascular complications.[15]
It is on the World Health Organization’s List of Essential Medicines.[16]
Medical uses
In many countries (e.g., Australia,[17][18] the United Kingdom,[19] and Russia[20]) it is commonly used for major depressive disorder. Fluvoxamine is also approved in the United States for obsessive–compulsive disorder (OCD),[21][9] and social anxiety disorder.[22] In Japan, it is also approved to treat OCD, social anxiety disorder, and major depressive disorder.[23][24] Fluvoxamine is indicated for children and adolescents with OCD.[25] The NICE guidelines in the United Kingdom have, as of 2005, authorized its use for obsessive-compulsive disorder in adults and adolescents of any age and children over the age of 7.[medical citation needed]
There is evidence that fluvoxamine is effective for generalised social anxiety in adults, although, as with other SSRIs, some of the results may be compromised by having been funded by pharmaceutical companies.[26][27] Of the SSRIs, however, fluvoxamine, paroxetine, and sertraline do appear consistent as viable treatments for generalised social anxiety.[28][29]
Fluvoxamine is also effective for treating a range of anxiety disorders in children and adolescents, including generalized anxiety disorder, social anxiety disorder, panic disorder, and separation anxiety disorder.[30][31][32]
The drug works long-term, and retains its therapeutic efficacy for at least one year.[33]
The average therapeutic dose for fluvoxamine is 100 to 300 mg/day, with 300 mg being the upper daily limit normally recommended. Obsessive-compulsive disorder, however, often requires higher doses; doses of up to 450 mg/day may be prescribed in this case.[34][35][36] The (off-label) upper daily limits for other serotonin-reuptake inhibitors used in the treatment of obsessive-compulsive disorder, by analogy, are 400 mg for sertraline,[37] 100 mg for paroxetine, 120 mg for both fluoxetine and citalopram, 60 mg for escitalopram and 300 mg for clomipramine.[38][39]
In any case with fluvoxamine, treatment is generally begun at 50 mg and increased in 50 mg increments every 4 to 7 days until a therapeutic optimum is reached.[40]
Adverse effects
Fluvoxamine’s side-effect profile is very similar to other SSRIs. Gastrointestinal side effects are characteristic of those receiving treatment with fluvoxamine.[3][21][17][19][41][42] However, compared to escitalopram and sertraline, fluvoxamine’s gastrointestinal profile may be less intense,[43] often being limited to nausea.[12] Mosapride has demonstrated efficacy in treating fluvoxamine-induced nausea.[44] It is also advised practice to divide total daily doses of fluvoxamine greater than 100 mg, with the higher fraction being taken in the evening (e.g., 50 mg at the beginning of the waking day and 200 mg at bedtime). In any case, high starting daily doses of fluvoxamine rather than the recommended gradual titration (starting at 50 mg and gradually titrating, up to 300 if necessary) may increase the likelihood of nausea.
Search by Keywords – Buy 54739-18-3 | Purchase 54739-18-3 | Order 54739-18-3 | Enquire 54739-18-3 | Price of 54739-18-3 | 54739-18-3 Cost | 54739-18-3 Supplier | 54739-18-3 Distributor | 54739-18-3 Manufacturer | 54739-18-3 Exporter | Fluvoxamine for Method Validation | Fluvoxamine for ANDA Filing | Fluvoxamine for Forced Degradation Studies | Fluvoxamine Identification Standards | Fluvoxamine for DMF Filing | Fluvoxamine
Buy Fluvoxamine (Luvox) Cas 54739-18-3
Buy Fluvoxamine (Luvox) Cas 54739-18-3
Buy Fluvoxamine (Luvox) Cas 54739-18-3
Buy Fluvoxamine (Luvox) Cas 54739-18-3
Buy Fluvoxamine (Luvox) Cas 54739-18-3
Buy Fluvoxamine (Luvox) Cas 54739-18-3
Buy Fluvoxamine (Luvox) Cas 54739-18-3
Buy Fluvoxamine (Luvox) Cas 54739-18-3
Buy Fluvoxamine (Luvox) Cas 54739-18-3
Buy Fluvoxamine (Luvox) Cas 54739-18-3
Buy Fluvoxamine (Luvox) Cas 54739-18-3
Buy Fluvoxamine (Luvox) Cas 54739-18-3
Buy Fluvoxamine (Luvox) Cas 54739-18-3
Fluvoxamine
- CAS No.
- 54739-18-3
- Chemical Name:
- Fluvoxamine
- Synonyms
- 2-[[5-methoxy-1-[4-(trifluoromethyl)phenyl]-pentylidene]amino]oxyethanamine;FLUVOXAMINE;Fluvoxamine USP/EP/BP;Fluvoxamine Impurity 7;Fluvoxamine in Methanol;Fluvoxamine See: F603500;Fluvoxamine Also See: F603500 ;δ-Methoxy-4′-(trifluoromethyl)valerophenone (E)-O-(2-aminoethyl)oxime;(E)-ω-Methoxy-4′-(trifluoromethyl)valerophenone O-(2-aminoethyl)oxime;5-Methoxy-4’-(triflluoromethyl)valerophenone(E)-O-(2-aminoethyl) oxime
- CBNumber:
- CB8468990
- Molecular Formula:
- C15H21F3N2O2
- Molecular Weight:
- 318.33
- MDL Number:
- MFCD00865345
- MOL File:
- 54739-18-3.mol
- MSDS File:
- SDS
- TDS File:
- TDS
| Product description | Number | Pack Size | Price |
| Fluvoxamine | FF29182 | 0.1g | $267.49 |
| Fluvoxamine | FF29182 | 0.25g | $445.82 |
| Fluvoxamine | FF29182 | 0.5g | $668.73 |
| Fluvoxamine | FF29182 | 1g | $957 |
| Fluvoxamine | FF29182 | 2g | $1355.76 |
| More product size | |||
| Melting point | 120-122.5°C |
|---|---|
| Boiling point | 370.6±52.0 °C(Predicted) |
| Density | 1.16±0.1 g/cm3(Predicted) |
| storage temp. | Sealed in dry,2-8°C |
| solubility | Chloroform (Sparingly), DMSO (Slightly), Methanol (Slightly) |
| form | Oil |
| pka | pKa 8.7 (Uncertain) |
| color | Colourless |
| InChI | InChI=1S/C15H21F3N2O2/c1-21-10-3-2-4-14(20-22-11-9-19)12-5-7-13(8-6-12)15(16,17)18/h5-8H,2-4,9-11,19H2,1H3/b20-14+ |
| InChIKey | CJOFXWAVKWHTFT-XSFVSMFZSA-N |
| SMILES | C(=N/OCCN)(\C1=CC=C(C(F)(F)F)C=C1)/CCCCOC |
| CAS DataBase Reference | 54739-18-3(CAS DataBase Reference) |
| FDA UNII | O4L1XPO44W |
| NCI Dictionary of Cancer Terms | fluvoxamine |
| ATC code | N06AB08 |
| NIST Chemistry Reference | Fluvoxamine(54739-18-3) |
SAFETY
Risk and Safety Statements
| Symbol(GHS) |    GHS07,GHS09,GHS06 |
|---|---|
| Signal word | Danger |
| Hazard statements | H302-H335-H331-H410-H319 |
| Precautionary statements | P273-P391-P501-P264-P280-P305+P351+P338-P337+P313P-P261-P271-P304+P340-P311-P321-P403+P233-P405-P501-P264-P270-P301+P312-P330-P501 |
| REACH Registrations | Active |
Fluvoxamine price More Price(55)
| Manufacturer | Product number | Product description | CAS number | Packaging | Price | Updated | Buy |
|---|---|---|---|---|---|---|---|
| Biosynth | FF29182 | Fluvoxamine | 54739-18-3 | 0.1g | $267.49 | 2026-06-04 | Buy |
| Biosynth | FF29182 | Fluvoxamine | 54739-18-3 | 0.25g | $445.82 | 2026-06-04 | Buy |
| Biosynth | FF29182 | Fluvoxamine | 54739-18-3 | 0.5g | $668.73 | 2026-06-04 | Buy |
| Biosynth | FF29182 | Fluvoxamine | 54739-18-3 | 1g | $957 | 2026-06-04 | Buy |
| Biosynth | FF29182 | Fluvoxamine | 54739-18-3 | 2g | $1355.76 | 2026-06-04 | Buy |
Fluvoxamine Chemical Properties, Uses, Production
Chemical Properties
Colourless Oil
Originator
Floxyfral, Kali-Duphar ,Switz. ,1983
History
The development of Fluvoxamine began in the 1970s, led by a research team at the Belgian pharmaceutical company Solvay. As the first successfully commercialized selective serotonin reuptake inhibitor (SSRI), fluvoxamine was designed and synthesized to exert its antidepressant effect by highly selectively inhibiting the presynaptic serotonin transporter, while exhibiting a higher safety profile compared to tricyclic antidepressants. This compound received its first clinical approval and market launch in Switzerland in 1983, marking the beginning of the SSRI era. Leading researchers in psychopharmacology, including C. M. van Hout, systematically elucidated the pharmacological properties and clinical efficacy of fluvoxamine. With the expansion of its clinical applications, fluvoxamine has also established a therapeutic role in indications such as obsessive-compulsive disorder, and during the COVID-19 pandemic, its re-evaluation as a potential immunomodulator sparked renewed research interest, reflecting its evolution from a classic antidepressant to a multi-purpose psychopharmacological drug.
Uses
A selective serotonin reuptake inhibitor (SSRI) used as an anti-depressant.
Definition
ChEBI: Fluvoxamine is an oxime O-ether that is benzene substituted by a (1E)-N-(2-aminoethoxy)-5-methoxypentanimidoyl group at position 1 and a trifluoromethyl group at position 4. It is a selective serotonin reuptake inhibitor that is used for the treatment of obsessive-compulsive disorder. It has a role as an antidepressant, a serotonin uptake inhibitor and an anxiolytic drug. It is a 5-methoxyvalerophenone O-(2-aminoethyl)oxime and a member of (trifluoromethyl)benzenes. It is functionally related to a (trifluoromethyl)benzene.
Manufacturing Process
20.4 mmol (5.3 g) of 5-methoxy-4′-trifluoromethylvalerophenone (MP 43°C to 44°C), 20.5 mmol (3.1 g) of 2-aminooxyethylamine dihydrochloride and 10 ml of pyridine were refluxed for 15 hr in 20 ml of absolute ethanol. After evaporating the pyridine and the ethanol in vacuo, the residue was dissolved in water. This solution was washed with petroleum ether and 10 ml of 50% sodium hydroxide solution were then added. Then three extractions with 40 ml of ether were carried out. The ether extract was washed successively with 20 ml of 5% sodium bicarbonate solution and 20 ml of water. After drying on sodium sulfate, the ether layer was evaporated in vacuo. Toluene was then evaporated another three times (to remove the pyridine) and the oil thus obtained was dissolved in 15 ml of absolute ethanol. An equimolar quantity of maleic acid was added to the solution and the solution was then heated until a clear solution was obtained. The ethanol was then removed in vacuo and the residue was crystallized from 10 ml of acetonitrile at +5°C. After sucking off and washing with cold acetonitrile, it was dried in air. The MP of the resulting compound was 120°C to 121.5°C.
brand name
Luvox (Solvay Pharmaceuticals);Faverin.
Therapeutic Function
Antidepressant
General Description
The E-isomer of fluvoxamine (Luvox) can fold after protonation to the β-arylamine–like grouping. Here,the “extra” hydrophobic group is aliphatic.
Hazard
A poison.
Biological Activity
fluvoxamineis is an antidepressant which pharmacologically functions as a selective serotonin reuptake inhibitor. serotonin, also known as 5-ht, is amonoamine neurotransmitter with various physiological functions such as mood, appetite, and sleep[1].
Mechanism of action
Fluvoxamine is a highly selective inhibitor of 5-HT reuptake at the presynaptic membrane. Potency data from in vitro affinity studies suggest that fluvoxamine is less potent than the other SSRIs (e.g., paroxetine, sertraline, and citalopram). Its mechanism of action is similar to that of the other SSRIs. Fluvoxamine appears to have little or no effect on the reuptake of NE or dopamine. In vitro studies have demonstrated that fluvoxamine possesses virtually no affinity for other neuroreceptors. Its onset of action is similar to the other SSRIs (2–4 weeks).
Pharmacokinetics
Fluvoxamine is well absorbed, with a bioavailability of approximately 50%, probably because of first-pass metabolism. At steady-state doses, fluvoxamine demonstrates nonlinear pharmacokinetics over a dosage range of 100 to 300 mg/day, which results in higher plasma concentrations at higher doses than would be predicted by lower-dose kinetics (single dose, 15 hours; multiple dosing, 22 hours). Food does not significantly affect oral bioavailability. The mean apparent volume of distribution for fluvoxamine reflects its lipophilic nature, extensive tissue distribution, and protein binding. Fluvoxamine is distributed into breast milk. Fluvoxamine is preferentially metabolized by CYP2D6 in the liver by O-demethylation to its alcohol metabolite, which subsequently is oxidized to a carboxylic acid. Oxidative deamination and nine other metabolites have been identified, none of which shows significant pharmacological activity.
Clinical Use
Fluvoxamine is approved for use in obsessive-compulsive disorders.
Side effects
The adverse effects for fluvoxamine include symptoms of drowsiness, nausea or vomiting, abdominal pain, tremors, sinus bradycardia, and mild anticholinergic symptoms. Toxic doses could produce seizures and severe bradycardia.
in vitro
fluvoxamine effectively inhibited 5-ht uptake by blood platelets and brain synaptosomes [1].fluvoxamine (10 mg/kg) increased [5-ht]ex levels in all brain areas and increased [da]ex levels in the striatum. fluvoxamine (10 mg/kg) in combination with of quetiapine (10 mg/kg) increased [da]ex and [5-ht]ex levels in all brain areas when compared with baseline. the combination produced a significant increase of [da]ex levels in the prefrontal cortex and thalamus whereas neither quetiapine nor fluvoxamine in monotherapy affected [da]ex levels [2]. fluvoxamine induced antiallodynic effects on neuropathic pain via descending 5-ht fibers and spinal 5-ht2a or 5-ht2c receptors, and the antinociception on acute mechanical pain via 5-ht3 receptors [3].
in vivo
single administration of fluvoxamine (10 and 30 mg/kg, i.p.) dose-dependently enhanced synaptic efficacy in the hippocampo-mpfc pathway [4]. fluvoxamine (10 and 30 mg/kg, i.p.) treatment suppressed long-term potentiation (ltp) in the hippocampal ca1 field of anesthetized rats. nan-190 (0.5 mg/kg, i.p), the 5-ht(1a) receptor antagonist, completely reversed the fluvoxamine (30 mg/kg, i.p.) suppression of ltp [5].
Drug interactions
In vitro studies have shown fluvoxamine to be a potent inhibitor of CYP1A2, to inhibit CYP3A4 and CYP2C19, and to weakly inhibit CYP2D6. The bioavailability of fluvoxamine is significantly decreased in smokers compared with nonsmokers, possibly because of induction of CYP1A metabolism of fluvoxamine. Therefore, interactions with drugs that inhibit CYP1A2 also should be considered (e.g., theophylline and caffeine).
References
[1]. claassen v,davies je,hertting g,placheta p. fluvoxamine, a specific 5-hydroxytryptamine uptake inhibitor.br j pharmacol.1977 aug;60(4):505-16.
[2]. denys d1,klompmakers aa,westenberg hg. synergistic dopamine increase in the rat prefrontal cortex with the combination of quetiapine and fluvoxamine.psychopharmacology (berl).2004 nov;176(2):195-203. epub 2004 may 11.
[3]. honda m1,uchida k,tanabe m,ono h. fluvoxamine, a selectiveserotoninreuptake inhibitor, exerts its antiallodynic effects on neuropathic pain in mice via 5-ht2a/2c receptors.neuropharmacology.2006 sep;51(4):866-72. epub 2006 jul 17.
[4]. ohashi s1,matsumoto m,otani h,mori k,togashi h,ueno k,kaku a,yoshioka m. changes in synaptic plasticity in the rat hippocampo-medial prefrontal cortex pathway induced by repeated treatments with fluvoxamine.brain res.2002 sep 13;949(1-2):131-8.
[5]. kojima t1,matsumoto m,togashi h,tachibana k,kemmotsu o,yoshioka m. fluvoxamine suppresses the long-term potentiation in the hippocampal ca1 field of anesthetized rats: an effect mediated via 5-ht1a receptors.brain res.2003 jan 3;959(1):165-8.
Fluvoxamine Preparation Products And Raw materials
Raw materials
Preparation Products
-
Fluvoxamine | 54739-18-3 – ChemicalBook
Jul 18, 2026 · Fluvoxamine (CAS 54739-18-3) information, including chemical …
-
Boiling point: 370.6±52.0 °C (Predicted)
-
Melting point: 120-122.5°C
-
Density: 1.16±0.1 g/cm3 (Predicted)
-
storage temp.: Sealed in dry,2-8°C
-
-
Fluvoxamine – synhet.com
SynHet is professional manufacturer and supplier of Fluvoxamine, 54739-18-3 and related synthetic chemical products. Fluvoxamine, …
-
Fluvoxamine | 54739-18-3 – Chemicea
Buy Fluvoxamine CAS No-54739-18-3 Online from Chemicea Pharma, Manufacturer and Exporter of Fluvoxamine
Fluvoxamine | 54739-18-3 | SynZeal
Fluvoxamine can be used for the analytical method development, method validation (AMV), Quality Controlled (QC) application for …
-
Fluvoxamine | CAS No: 54739-18-3
Buy high quality Fluvoxamine, CAS No: 54739-18-3 from AquigenBio, the leading Pharmaceutical Impurities Manufacturer and Supplier.
-
Fluvoxamine | 54739-18-3 – MilliporeSigma
Find documentation for the products that you have recently purchased in the Document Library. Visit the Document Library. Our …
-
Fluvoxamine | CS-T-54993 | CAS 54739-18-3 | Clearsynth
Buy Fluvoxamine from Clearsynth. View CAT No. CS-T-54993, CAS No. 54739-18-3, molecular formula, molecular weight, stock …
-
Fluvoxamine | 54739-18-3 | FF29182 | Biosynth
Buy Fluvoxamine (FF29182 54739-18-3) online. Biosynth supplies catalog, bulk, and custom products for the life sciences and …
-
Fluvoxamine 54739-18-3 | MedChemExpress
MedChemExpress provides Fluvoxamine CAS 54739-18-3, related Reference Standards, Isotope-Labeled or GMP Grade …
-
Fluvoxamine | CAS No- 54739-18-3 | Simson Pharma Limited
Buy High-Quality Fluvoxamine Reference Standards, Impurity Standards, Metabolites, Analytical Standards, Pharmacopoeial & Non …
Reviews
There are no reviews yet.